Koç A, Guney I, Kızılarslanoglu M C, Gonulalan G, Deniz C D, Saçkan F, Ergül F, Sözen M
Dept. of Internal Medicine, Akşehir State Hospital, Konya, Turkey.
Dept. of Nephrology, Konya City Hospital, Konya, Turkey.
Acta Endocrinol (Buchar). 2023 Jul-Sep;19(3):286-291. doi: 10.4183/aeb.2023.286. Epub 2024 Feb 1.
Inflammation-related markers may predict cardiovascular diseases.
In this study, it was aimed to assess pentraxin-3 (PTX-3) levels and its relationship with carotid intima-media thickness (CIMT) and high-sensitive C-reactive protein (hsCRP) in patients with subclinical hypothyroidism.
Prospective cross-sectional study.
This study included 60 patients (aged 30-60 years) with subclinical hypothyroidism and 30 healthy volunteers as controls. The demographic characteristics and anthropometric measurements were performed in all patients and controls. In addition, sonographic carotid artery examination, thyroid functional tests, lipid profile, hsCRP, and PTX-3 levels of the participants were investigated.
The PTX-3, hsCRP levels and CIMT were higher in patients with subclinical hypothyroidism when compared to controls (p=0.008, p=0.001, p<0.001, respectively). The PTX-3 level was strongly correlated with hsCRP (r=0.865; p<0.001), but no such correlation was detected with CIMT (r=-0.255; p=0.50). In binominal logistic regression analysis, it was found that CIMT and serum uric acid levels were independent parameters associated with subclinical hypothyroidism. In ROC analysis, a cut-off value of >3.75 ng/mL for serum PTX-3 level predicted subclinical hypothyroidism with a sensitivity of 60% and specificity of 60.7% (AUC: 0.672, p=0.004).
Showing inflammation and endothelial dysfunction, the PTX-3 may be a helpful marker in patients with subclinical hypothyroidism associated with increased risk for cardiovascular disease.
炎症相关标志物可能预测心血管疾病。
本研究旨在评估亚临床甲状腺功能减退患者中五聚体-3（PTX-3）水平及其与颈动脉内膜中层厚度（CIMT）和高敏C反应蛋白（hsCRP）的关系。
前瞻性横断面研究。
本研究纳入60例年龄在30至60岁之间的亚临床甲状腺功能减退患者和30名健康志愿者作为对照。对所有患者和对照进行人口统计学特征和人体测量。此外，对参与者进行颈动脉超声检查、甲状腺功能测试、血脂谱、hsCRP和PTX-3水平检测。
与对照组相比，亚临床甲状腺功能减退患者的PTX-3、hsCRP水平和CIMT更高（分别为p = 0.008、p = 0.001、p < 0.001）。PTX-3水平与hsCRP密切相关（r = 0.865；p < 0.001），但与CIMT无此相关性（r = -0.255；p = 0.50）。在二项逻辑回归分析中，发现CIMT和血清尿酸水平是与亚临床甲状腺功能减退相关的独立参数。在ROC分析中，血清PTX-3水平>3.75 ng/mL的临界值预测亚临床甲状腺功能减退的敏感性为60%，特异性为60.7%（AUC：0.672，p = 0.004）。
PTX-3显示出炎症和内皮功能障碍，可能是亚临床甲状腺功能减退且心血管疾病风险增加患者的有用标志物。
